Briseno Andres Ruiz Sells 9,550 Shares of IDEAYA Biosciences (NASDAQ:IDYA) Stock

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) CAO Briseno Andres Ruiz sold 9,550 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total transaction of $382,095.50. Following the completion of the transaction, the chief accounting officer directly owned 26,466 shares in the company, valued at $1,058,904.66. This represents a 26.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences stock traded down $0.68 during trading hours on Thursday, hitting $37.28. The company had a trading volume of 983,834 shares, compared to its average volume of 1,157,303. The firm has a market cap of $3.28 billion, a P/E ratio of -23.30 and a beta of -0.09. IDEAYA Biosciences, Inc. has a 1 year low of $21.33 and a 1 year high of $40.58. The company has a 50-day moving average price of $31.16 and a two-hundred day moving average price of $32.57.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The business had revenue of $6.56 million for the quarter, compared to analyst estimates of $5.04 million. IDEAYA Biosciences’s quarterly revenue was down 39.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.82) EPS. As a group, equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -4.13 EPS for the current year.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of IDYA. Janus Henderson Group PLC increased its holdings in IDEAYA Biosciences by 1.1% during the first quarter. Janus Henderson Group PLC now owns 7,265,253 shares of the company’s stock valued at $242,023,000 after buying an additional 78,797 shares during the period. Vanguard Group Inc. lifted its holdings in IDEAYA Biosciences by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 5,019,324 shares of the company’s stock worth $173,518,000 after buying an additional 97,116 shares during the period. State Street Corp lifted its holdings in IDEAYA Biosciences by 27.6% during the fourth quarter. State Street Corp now owns 4,134,641 shares of the company’s stock worth $142,935,000 after buying an additional 893,707 shares during the period. Baker BROS. Advisors LP boosted its position in IDEAYA Biosciences by 10.5% during the 4th quarter. Baker BROS. Advisors LP now owns 3,618,826 shares of the company’s stock valued at $125,103,000 after acquiring an additional 343,382 shares in the last quarter. Finally, Fiera Capital Corp boosted its position in IDEAYA Biosciences by 32.6% during the 4th quarter. Fiera Capital Corp now owns 2,437,262 shares of the company’s stock valued at $84,256,000 after acquiring an additional 599,295 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

IDYA has been the topic of several research analyst reports. Royal Bank Of Canada dropped their price objective on IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating on the stock in a research note on Tuesday. The Goldman Sachs Group lifted their target price on IDEAYA Biosciences from $31.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, April 14th. Wells Fargo & Company upped their target price on IDEAYA Biosciences from $44.00 to $48.00 and gave the stock an “overweight” rating in a report on Tuesday, April 14th. Guggenheim increased their price target on IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Tuesday, April 21st. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.25.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.